Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma

被引:26
作者
Blasi, MA
Giammaria, D
Balestrazzi, E
机构
[1] Univ Aquila, Dept Ophthalmol, I-67100 Laquila, Italy
[2] Univ Cattolica Sacro Cuore, Dept Ophthalmol, Rome, Italy
关键词
D O I
10.1016/j.ajo.2005.06.057
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To evaluate the efficacy and safety of topical imiquimod 5% cream for the treatment of eyelid basal cell carcinoma. DESIGN: Two interventional case reports. METHODS: Imiquimod 5% cream was applied topically once daily, 3 days a week for 8 to 12 weeks, in two patients affected by eyelid nodular basal cell carcinoma. Patients were followed up clinically with slit-lamp examination for evidence of tumor disappearance or recurrence, and local and systemic side effects. RESULTS: Complete clinical response was obtained in both patients. No severe local side effects were ob, served. Patients did not show any local recurrence after 1 year. CONCLUSIONS: Topical imiquimod 5% cream seems to be a useful treatment for eyelid nodular basal cell carcinoma in selected cases, but further long-term studies are needed to assess the efficacy and safety of this approach.
引用
收藏
页码:1136 / 1139
页数:4
相关论文
共 7 条
[1]   Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream [J].
Beutner, KR ;
Geisse, JK ;
Helman, D ;
Fox, TL ;
Ginkel, A ;
Owens, ML .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 41 (06) :1002-1007
[2]   Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota [J].
Cook, BE ;
Bartley, GB .
OPHTHALMOLOGY, 1999, 106 (04) :746-750
[3]   Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway [J].
Hemmi, H ;
Kaisho, T ;
Takeuchi, O ;
Sato, S ;
Sanjo, H ;
Hoshino, K ;
Horiuchi, T ;
Tomizawa, H ;
Takeda, K ;
Akira, S .
NATURE IMMUNOLOGY, 2002, 3 (02) :196-200
[4]   Topical imiquimod treatment for nodular basal cell carcinomas: An open-label series [J].
Huber, A ;
Huber, JD ;
Skinner, RB ;
Kuwahara, RT ;
Haque, R ;
Amonette, RA .
DERMATOLOGIC SURGERY, 2004, 30 (03) :429-430
[5]   The Australian Mohs database, part II - Periocular basal cell carcinoma outcome at 5-year follow-up [J].
Malhotra, R ;
Huilgol, SC ;
Huynh, NT ;
Selva, D .
OPHTHALMOLOGY, 2004, 111 (04) :631-636
[6]   Imiquimod applied topically: a novel immune response modifier and new class of drug [J].
Miller, RL ;
Gerster, JF ;
Owens, ML ;
Slade, HB ;
Tomai, MA .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1999, 21 (01) :1-14
[7]   Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma - Comparison of dosing regimens [J].
Shumack, S ;
Robinson, J ;
Kossard, S ;
Golitz, L ;
Greenway, H ;
Schroeter, A ;
Andres, K ;
Amies, M ;
Owens, M .
ARCHIVES OF DERMATOLOGY, 2002, 138 (09) :1165-1171